UA26401C2 - Заміщеhі 3-аміhохіhуклідиhи - Google Patents

Заміщеhі 3-аміhохіhуклідиhи

Info

Publication number
UA26401C2
UA26401C2 UA93003970A UA93003970A UA26401C2 UA 26401 C2 UA26401 C2 UA 26401C2 UA 93003970 A UA93003970 A UA 93003970A UA 93003970 A UA93003970 A UA 93003970A UA 26401 C2 UA26401 C2 UA 26401C2
Authority
UA
Ukraine
Prior art keywords
halogen
alkyl
alkylamino
alkoxy
atoms
Prior art date
Application number
UA93003970A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Іто Фумітака
Ито Фумитака
Кокура Тосіхіде
Кокура Тосихиде
Hакане Масамі
Сатаке Куніо
Сатаке Кунио
Вакабайасі Хіроакі
Вакабайаси Хироаки
Original Assignee
Пфайзер Інк.
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Інк., Пфайзер Инк. filed Critical Пфайзер Інк.
Publication of UA26401C2 publication Critical patent/UA26401C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
UA93003970A 1991-05-22 1992-05-19 Заміщеhі 3-аміhохіhуклідиhи UA26401C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14682691 1991-05-22
PCT/US1992/004002 WO1992020676A1 (fr) 1991-05-22 1992-05-19 3-aminoquinuclidines substituees

Publications (1)

Publication Number Publication Date
UA26401C2 true UA26401C2 (uk) 1999-08-30

Family

ID=15416402

Family Applications (1)

Application Number Title Priority Date Filing Date
UA93003970A UA26401C2 (uk) 1991-05-22 1992-05-19 Заміщеhі 3-аміhохіhуклідиhи

Country Status (25)

Country Link
EP (1) EP0585328B1 (fr)
KR (1) KR100246065B1 (fr)
CN (1) CN1041827C (fr)
AT (1) ATE211743T1 (fr)
AU (1) AU658898B2 (fr)
BR (1) BR9206044A (fr)
CA (1) CA2109415C (fr)
CZ (1) CZ247993A3 (fr)
DE (2) DE9290057U1 (fr)
DK (1) DK0585328T3 (fr)
EG (1) EG20218A (fr)
ES (1) ES2168260T3 (fr)
FI (1) FI935134A (fr)
HU (1) HUT65771A (fr)
IE (1) IE921662A1 (fr)
IL (1) IL101960A (fr)
MX (1) MX9202449A (fr)
NO (1) NO305173B1 (fr)
NZ (2) NZ272941A (fr)
PL (4) PL170513B1 (fr)
PT (1) PT100514B (fr)
RU (1) RU2092486C1 (fr)
UA (1) UA26401C2 (fr)
WO (1) WO1992020676A1 (fr)
ZA (1) ZA923773B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
CA2109613C (fr) * 1991-06-20 1996-11-19 John Adams Lowe Iii Derives fluoroalcoxybenzylamines d'heterocycles azotes
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
ATE208376T1 (de) * 1992-08-19 2001-11-15 Pfizer Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
JP2656699B2 (ja) * 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
PT675886E (pt) * 1992-12-10 2000-12-29 Pfizer Heterociclos nao aromaticos com substituintes aminometileno e sua utilizacao como antagonistas da substancia p
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
DK0708771T3 (da) * 1993-07-15 1999-06-21 Pfizer Benzyloxyquinuclidiner som substans P antagonister
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
EP0719253B1 (fr) * 1993-09-17 2004-04-28 Pfizer Inc. Piperidines 3-amino-5-carboxy-substituees et pyrrolidines 3-amino-4-carboxy-substituees utilisees comme antagonistes de tachykinine
EP0653208A3 (fr) * 1993-11-17 1995-10-11 Pfizer Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
EP0659409A3 (fr) * 1993-11-23 1995-08-09 Pfizer Antagonistes de la substance P pour l'inhibition de l'angiogénése.
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CN1414953A (zh) 1999-11-03 2003-04-30 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5－羟色胺重摄取的用途
AU7334901A (en) 2000-07-11 2002-01-21 Du Pont Pharm Co Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
MX2007000428A (es) 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
CA2615403C (fr) 2005-07-15 2015-06-16 Amr Technology, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (fr) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
ES2662072T3 (es) 2009-05-12 2018-04-05 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
EP2429293B1 (fr) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company FORMES CRISTALLINES DE (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN -6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE ET LEURS UTILISATIONS
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 ***-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
CA2882950A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composes inhibiteurs de erk
LT2925888T (lt) 2012-11-28 2018-01-10 Merck Sharp & Dohme Corp. Vėžio gydymo kompozicijos ir būdai
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas

Also Published As

Publication number Publication date
FI935134A0 (fi) 1993-11-19
EP0585328B1 (fr) 2002-01-09
AU658898B2 (en) 1995-05-04
FI935134A (fi) 1993-11-19
PL172069B1 (pl) 1997-07-31
AU1927592A (en) 1992-12-30
HUT65771A (en) 1994-07-28
PL170525B1 (en) 1996-12-31
PT100514A (pt) 1993-09-30
CA2109415A1 (fr) 1992-11-23
KR100246065B1 (en) 2000-04-01
ZA923773B (en) 1993-11-22
DE69232334D1 (de) 2002-02-14
WO1992020676A1 (fr) 1992-11-26
HU9303307D0 (en) 1994-03-28
CN1041827C (zh) 1999-01-27
MX9202449A (es) 1993-03-01
IL101960A (en) 1999-03-12
NO305173B1 (no) 1999-04-12
CA2109415C (fr) 1998-12-29
PL171921B1 (pl) 1997-06-30
DE9290057U1 (de) 1994-01-05
PT100514B (pt) 1999-06-30
ES2168260T3 (es) 2002-06-16
DE69232334T2 (de) 2002-11-14
PL170513B1 (en) 1996-12-31
DK0585328T3 (da) 2002-02-11
IL101960A0 (en) 1994-04-12
IE921662A1 (en) 1992-12-02
NZ242880A (en) 1995-10-26
BR9206044A (pt) 1995-03-01
NO934195L (no) 1993-11-19
EG20218A (en) 1997-11-30
NZ272941A (en) 1997-05-26
CZ247993A3 (en) 1994-07-13
RU2092486C1 (ru) 1997-10-10
CN1068571A (zh) 1993-02-03
EP0585328A1 (fr) 1994-03-09
NO934195D0 (no) 1993-11-19
ATE211743T1 (de) 2002-01-15

Similar Documents

Publication Publication Date Title
UA26401C2 (uk) Заміщеhі 3-аміhохіhуклідиhи
HUP0004333A2 (hu) Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0301690A2 (hu) Szinergikus eljárások és készítmények rák kezelésére
HUP0105081A2 (hu) Triazolo[4,5-d]pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
SE8107537L (sv) Nya derivat av heterocykliska aminoalcoyler, deras framstellningssett och deras terapeutiska anvendning
AU1884092A (en) Novel derivatives of perhydroisoindole and preparation thereof
EP0163599A3 (en) Pyrimidopyrimidine derivatives, processes for producing them, pharmaceutical compositions containing them and their use as anti-allergic agents
DK0870768T3 (da) Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler
CY1106257T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΙΔΑΖΙΝΟ [4,5-(b)]-ΙΝΔΟΛΗ -1-ΑΚΕΤΑΜΙΔΗ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΟΥ ΠΡΟΟΡΙΖΟΝΤΑΙ ΓΙΑ ΝΟΣΟΥΣ ΠΟΥ ΣΥΝΔΕΟΝΤΑΙ ΜΕ ΤΗ ΔΥΣΛΕΙΤΟΥΡΓΙΑ ΤΩΝ ΥΠΟΔΟΧΕΩΝ ΠEPΙΦEPΙΚΟΥ ΤΥΠΟΥ ΣΤΙΣ ΒΕΝΖΟΔΙΑΖΕΠΙΝΕΣ
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
FR2613365B1 (fr) Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
YU237990A (sh) Morfolinil derivati doksorubicina i postupak za njihovo dobijanje
NO172437C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidindionforbindelser
ES2043834T3 (es) Un procedimiento para preparar nuevos derivados de androsta-1,4-dien-3-ona sustituida en la posicion 17.
ATE204278T1 (de) Serotoninergische ergolin derivate
ATE247955T1 (de) Selenophen-antitumormittel
ES8300116A1 (es) Procedimiento para la obtencion de nuevos derivados de la tiazolo (3,2-a)pirimidina
SE8603589D0 (sv) Metylendioxifenantren- och stilbenderivat
HUP0002659A2 (hu) Benzo-5,6-ciklohepta[1,2-b]piridin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AU1234488A (en) New 2-(2,3-dihydro-2-oxo-3-benzofuranyl) acetic acid derivatives, processes for preparing them and the pharmaceutical compositions which contain them
AU1234588A (en) New acetamides derived from 2,3-dihydro-3-phenyl-2-benzofuranone, processes for preparing them and the pharmaceutical compositions which contain them
FI101071B (fi) Menetelmä terapeuttisesti käyttökelpoisten 3,4-dihydroisokinoliini-N-o ksidien valmistamiseksi
AU7458894A (en) 1,5-benzodiazepine derivatives useful as cck or gastrin antagonists
AR005834A1 (es) Esteres de derivados de 3-hidroxipiperidinmetanol, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, un procedimiento para preparar dicha composicion, un compuesto intermediario y un proceso para preparar un compuesto intermediario.
ES2136667T3 (es) Compuestos de etinil-alanina-amino-diol que tienen un grupo terminado en piperazinilo o un grupo terminado en piperazinil-alquilamino para el tratamiento de la hipertension.